HomeNew producsSpecialsMy accountFAQContact Us
Search
 

Use keywords to find the product you are looking for.

 
Categories
PGD2 Inhibitors
Chromoglycate / Indomethacin A+B
D-Cloprostenol
PGD2 Inhibitor Data
Ramatroban
SARMs
Ostarine 25mg / ml, 60ml
SARMs S4 25mg / ml, 60ml
SERMs
Clomiphene 3000mg, 60ml
Raloxifene 60mg /ml, 60ml
Tamoxifen (True Twenty) 1200mg, 60ml
Toremifene Citrate 1800mg, 30ml
Toremifene Citrate 3600mg, 60ml
b2 ADRENERGENIC AGONISTS
Albuterol 6mg/ml, 60ml
Clenbuterol 200mcg/ml, 30ml
Clenbuterol 200mcg/ml, 60ml
THYROID RELATED
T3 100mcg / ml, 60ml
T4 400mcg / ml, 60ml
AROMATASE INHIBITORS
Anastrozole 30mg, 30ml
Anastrozole 60mg, 60ml
Exemestane 300mg, 30ml
Exemestane 600mg, 60ml
Letrozole 150mg, 60ml
Letrozole 75mg / 30ml
IGF-1 PEPTIDES
IGF-1 DES 1 3, 1200mcg
IGF-1 Lr3 (10 vials)
IGF-1 Lr3 (3 Vials)
IGF-1 Lr3, 1200mcg
IGF-1 RH, 1200mcg
IGF-2 Lr3 1200mcg
MGF (IGF-1Ec) 2000mcg
IGF KITS
IGF-1 DES 1 3 KIT Receptor 1200mcg
IGF-1 Lr3 KIT Receptor 1200mcg
IGF-2 Lr3 Kit Receptor 1200mcg
MELANOTROPIN PEPTIDES
Melanotan II (10 vials) 100mg
Melanotan II 10mg
Melanotan II 30mg (3 Vials)
PT-141 (Bremalanotide) 10mg
SECRETOGOGUE PEPTIDES
CJC 1295 DAC, 2000mcg
CJC 1295 DAC, 2000mcg (3 vials)
CJC-1293 (GRF [1 29]) (3 vials)
CJC-1293 (GRF [1-29]) 2000mcg
GHRP-2 (4 Vials)
GHRP-2 (receptor) 5mg
GHRP-6 (receptor), 5mg
GHRP-6, (4 vials)
GnRH, 2000mcg
Hexarelin, 2000mcg
Ipamorelin, 2000mcg
Tesamorelin, 5 vial kit, 10mg
PEPTIDES
Ghrelex (D-Lys≥ GHRP-6)
Oxytocin, 1200iu
Phospho DSIP 1000mcg
Thymosin Beta 4, 8mg (4 vial pack)
MORE RESEARCH CHEM'S
AICAR 100mg
Dapoxetine HCL 30mg/ml, 30ml
GW1516, 150mg
Ketotifen Fumarate 120mg 60ml
Rimonabant 1200mg, 60ml
Yohimbine HCL, 10mg/ml, 30ml
SELECTIVE ANTI-ANDROGENS
Cortexolone 17-Alpha Propionate
Dutasteride 30mg, 60ml
Finasteride 150mg, 30ml
PDE5 INHIBITORS
Avanafil 50mg / ml, 60ml (Presale)
Sildenafil Citrate 750mg, 30ml
Tadalafil 30mg/ml, 30ml
Tadalafil 30mg/ml, 60ml
Vardenafil 300mg, 30ml
NOOTROPICS
Dihydroergotoxine (Ergotox)
Meclofenoxate, 60g
Pramiracetam 30g
Selegiline 300mg, 30ml
PROLACTIN ANTAGONISTS
Cabergoline 15mg, 30ml
Pramipexole Hydrochloride 60mg, 60ml
A.G.E. INHIBITORS / BREAKERS
ALT-711 (thiazolium chloride), 15g
Aminoguanidine HCL 4.5g, 60ml
TELOMERASE ACTIVATORS
Astragaloside IV 20mg / ml, 60ml
Cycloastragenol 5mg / ml, 60ml
HEPATOXICITY INHIBITORS
Silibinin 100mg/ml, 60ml
Ursodeoxycholic Acid, 30g
COMBINATION SPECIALS
AICAR + GW1516
Clen + Keto + Yohimbine
Tamox / Clom / Anast
MISCELLANEOUS
Custom Order: CO_061013NH
Expedited Service
Foreign Reship Fee
Legal Disclaimer for Download
Priority Shipping
Shipping Insurance $100-$299
Shipping Insurance $1000-$3000
Shipping Insurance $25-$99
Shipping Insurance $300-$599
Shipping Insurance $600-$999
Special Handling Fee $16
Special Handling Fee $30
test

IGF-1 DES 1 3, 1200mcg

 [GF13]
 $98.00 
IGF-1 DES 1 3, 1200mcg

DES(1-3)IGF

 

DES(1-3)IGF is a truncated form of IGF-1 with the tri-peptide structure Glycine-Proline-Glutamine cleaved from the N-terminus.  It has been isolated from and detected in numerous in vivo sources, including the human brain, bovine colostrum, and porcine uterus.[2]  In vitro studies demonstrate that at equal doses DES(1-3)IGF is ten times more potent than IGF-1 at stimulating hypertrophy and proliferation in cultured cells.[2]  It is likely generated through post-translational modification in the sequence of circulating mature IGF-1 via protease action.[2] 

 

The clearance rate from plasma of DES(1-3)IGF is four times faster than IGF-1, although the metabolic effects last for three to five times those of IGF-1.[2]  This is likely because DES(1-3)IGF remains in higher concentrations, post-clearance, in the extracellular space of target tissues than does IGF-1.[2]

 

DES(1-3)IGF holds promise for inflammatory bowel disease treatment, as it has been demonstrated in vivo to bind preferentially to gut tissue; it also, like other forms of IGF-1, should prove useful in treating catabolic states such as those from wasting diseases.

 

Ballard writes:

Des(1-3)IGF has not been tested clinically yet as success with IGF-I is considered essential before the extra expense of a more potent variant can be justified. Perhaps the more selective action of des(l-3)IGF-I on gut tissue warrants the evaluation of this growth factor as treatment for inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis, which have no other effective therapies.[2]

 

DES(1-3)IGF has been shown to stimulate proliferation in cultured myoblasts.[1] It binds to the same type I IGF receptor as IGF-1, but has a mere 1% binding affinity for the IGF binding proteins (IGFBP) found to be excreted by nearly all mammalian cells; thus, a much lower amount of DES(1-3)IGF is as biologically active as a higher dose of IGF-1.

 

Across a broad range of rat models (normal adult, diabetic, dexamethasone-treated, GH deficient, partial gut removal, chronic renal failure), DES(1-3)IGF demonstrated a robust and consistent one 1-3 times greater effect on body growth than IGF-1[2]:

 

Growth effects of des( lL3)1GF-I in rats occur in most tissues, although carcass fat is reduced and there is a trend for muscle weight to increase proportionately less than body weight. The selective increase in gut tissues is particularly striking as it occurs even in diabetes, where the condition itself stimulates gut growth and where insulin treatment has the opposite effect. Responses are demonstrated throughout the alimentary tract and are accompanied by improvements in nutrient uptake .[2]

 

Ballard speculates that the reason DES(1-3)IGF is more effective at gut healing than IGF-1 is due to the presence of many more than usual IGF binding proteins, which render IGF-1 ineffective.  Interestingly, the presence binding proteins in some cases have been demonstrated to increase the effectiveness of local wound healing.

 

DES(1-3)IGF is has not yet been seriously considered for treatment of human diseases, even though it holds promise according to research done on animal models, and exhibits some clinical differences from other available IGF forms.  In the future, as peptides are administered for therapy, the trend may change; DES(1-3)IGF has some unique advantages over other forms of IGF, primarily due to a lack of affinity for IGF binding proteins.  It should be noted that IGF binding proteins mediate some of the actions (both in terms of upregulation, and downregulation, depending on environment, circumstance, and type of IGFBP) of IGF-1; although DES(1-3)IGF has less affinity for the IGF receptor than IGF-1, the net result of a much lower affinity for IGFBPs is that a lower dose is more potent, although it binds indiscriminately.

 

*The latter article is intended for educational / informational purposes only. THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law.


This product was added to our catalog on Friday 04 February, 2011.
Reviews Add to Wish List
Quantity:     
Customers who bought this product also purchased
 
 
Shopping Cart
  Now in your cart 0 items
 
Your Account
 
Your Email Address
Your Password
 
Information
   
BestSellers
   
Featured
 
  AICAR 100mg
 
 

AICAR 100mg

$98.00
Comments

Write a review on this product!
Who's Online
  There currently are 20 guests and 
1 member online.